The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors
| Autor: | Hyoung Shin Lee, Sung Won Kim, Sun Yi Choi, Eun Nam Lee, Dong Kun Lee, Kang Dae Lee, Jong Chul Hong, Heon-Soo Park, Myung Koo Kang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Proto-Oncogene Proteins B-raf medicine.medical_specialty Lymphatic metastasis Pathology Papillary thyroid microcarcinoma endocrine system diseases Papillary Thyroid Microcarcinoma Polymerase Chain Reaction Thyroid carcinoma Surgical oncology Internal medicine Medicine Humans Thyroid Neoplasms Neoplasm Staging Retrospective Studies business.industry Research Follow up studies Middle Aged Prognosis Carcinoma Papillary BRAF V600E BRAF mutation Lymphatic Metastasis Risk stratification Mutation (genetic algorithm) Mutation Surgery Female business Follow-Up Studies |
| Zdroj: | World Journal of Surgical Oncology |
| ISSN: | 1477-7819 |
| Popis: | Background The BRAFV600E mutation, which accounts for about 60–80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAFV600E mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear. Methods We performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the prevalence of the BRAFV600E mutation. The associations between the BRAFV600E mutation and clinicopathologic characteristics were analyzed. Results The BRAFV600E mutation was observed in 72 patients (71.3%). There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAFV600E mutant group and wild group. Conclusions The BRAFV600E mutation is not significantly associated with prognostic factors in PTMC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink